{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:50:26Z","timestamp":1791276626093,"version":"4.1.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Takeda Canada Inc. Medical"},{"name":"Taylor Paton and Andrew Ho of Pentavere Research Group"},{"DOI":"10.13039\/100016040","name":"Takeda Canada Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016040","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Bowel urgency is a burdensome symptom of inflammatory bowel disease (IBD) that greatly impacts quality of life. This study evaluated vedolizumab effectiveness on bowel urgency in Canadian patients with ulcerative colitis (UC) and Crohn\u2019s disease (CD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with moderately to severely active UC or CD with baseline Urgency Numeric Rating Scale (UNRS) scores enrolled in the Canadian Patient Support Program (July 2024\u2013March 2025) were included. Bowel urgency and clinical endpoints were evaluated at 2, 6, and 14\u2009weeks. Clinically meaningful improvement (CMI) was defined as UNRS change from baseline \u22653 among patients with baseline UNRS \u22653. UC clinical remission was defined as pM (partial Mayo) score &amp;lt;3. CD clinical response was defined as Harvey-Bradshaw Index (HBI) decrease \u22653 and \u226525% from baseline; remission as HBI &amp;lt;5.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 412 vedolizumab-treated patients (319 UC, 93 CD), most were bio-na\u00efve (UC: 89%, CD: 63%) with median disease durations of 4\u2009years (UC) and 7\u2009years (CD). At baseline, 268 (84%) UC and 74 (80%) CD patients had UNRS \u22653. Median time to CMI was 6\u2009weeks in both cohorts. By week 14, UC patients experienced a 5-point median UNRS reduction (80%) and CD patients a 4-point reduction (62%). Patients achieving CMI at weeks 6 and 14 were significantly more likely to achieve clinical remission. Week 2 urgency outcomes were significant predictors of later outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Most UC and CD patients achieved CMI by 6\u2009weeks. CMI was significantly associated with validated clinical outcomes, demonstrating real-world effectiveness of vedolizumab in reducing bowel urgency.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jcag\/gwag031","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:16:50Z","timestamp":1785237410000},"page":"320-326","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of vedolizumab to reduce bowel urgency in a Canadian real-world inflammatory bowel disease cohort"],"prefix":"10.1093","volume":"9","author":[{"given":"Parul","family":"Tandon","sequence":"first","affiliation":[{"name":"University Health Network, University of Toronto Division of Gastroenterology and Hepatology, , Toronto, Ontario, M5T2S5,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Leung","sequence":"additional","affiliation":[{"name":"University of British Columbia Division of Gastroenterology, , Vancouver, British Columbia, V5Z 1M9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Ward","sequence":"additional","affiliation":[{"name":"Takeda Canada Inc. Toronto, Ontario, M5H 4E3,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Wadhwa","sequence":"additional","affiliation":[{"name":"Takeda Canada Inc. Toronto, Ontario, M5H 4E3,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Weiss","sequence":"additional","affiliation":[{"name":"Pentavere Research Group Inc. , Toronto, Ontario, M6G 1A1,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Moulson","sequence":"additional","affiliation":[{"name":"Pentavere Research Group Inc. , Toronto, Ontario, M6G 1A1,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Pettengell","sequence":"additional","affiliation":[{"name":"Pentavere Research Group Inc. , Toronto, Ontario, M6G 1A1,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7421-9764","authenticated-orcid":false,"given":"Robert","family":"Battat","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, Quebec H2X 0A9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"2026100603513817300_gwag031-B1","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1093\/jcag\/gwad020","article-title":"The 2023 impact of inflammatory bowel disease in Canada: epidemiology of IBD","volume":"6","author":"Coward","year":"2023","journal-title":"J Can Assoc Gastroenterol"},{"key":"2026100603513817300_gwag031-B2","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"2026100603513817300_gwag031-B3","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"2026100603513817300_gwag031-B4","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/MIB.0000000000000620","article-title":"Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases","volume":"22","author":"Mikocka-Walus","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2026100603513817300_gwag031-B5","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.crohns.2012.01.007","article-title":"Restoration of quality of life of patients with inflammatory bowel disease after one year with antiTNF\u03b1 treatment","volume":"6","author":"Casellas","year":"2012","journal-title":"J Crohns Colitis"},{"key":"2026100603513817300_gwag031-B6","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1080\/14656566.2016.1179281","article-title":"Maintenance therapy options for ulcerative colitis","volume":"17","author":"Chaparro","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"2026100603513817300_gwag031-B7","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn\u2019s disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2026100603513817300_gwag031-B8","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.14309\/ajg.0000000000002450","article-title":"Bowel urgency in ulcerative colitis: current perspectives and future directions","volume":"118","author":"Dubinsky","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2026100603513817300_gwag031-B9","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/ecco-jcc\/jjac136","article-title":"What are the unmet needs and most relevant treatment outcomes according to patients with inflammatory bowel disease? A qualitative patient preference study","volume":"17","author":"Bots","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026100603513817300_gwag031-B10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s41687-024-00802-8","article-title":"Patient perception of bowel urgency and remission in moderately to severely active Crohn\u2019s disease or ulcerative colitis: a qualitative study","volume":"8","author":"Bewtra","year":"2024","journal-title":"J Patient Rep Outcomes"},{"key":"2026100603513817300_gwag031-B11","doi-asserted-by":"publisher","first-page":"otae001","DOI":"10.1093\/crocol\/otae001","article-title":"Association of bowel urgency with quality-of-life measures in patients with moderately-to-severely active ulcerative colitis: results from phase 3 LUCENT-1 (induction) and LUCENT-2 (maintenance) studies","volume":"6","author":"Snider","year":"2024","journal-title":"Crohns Colitis 360"},{"key":"2026100603513817300_gwag031-B12","doi-asserted-by":"publisher","first-page":"otac035","DOI":"10.1093\/crocol\/otac035","article-title":"Living with inflammatory bowel disease: online surveys evaluating patient perspectives on treatment satisfaction and health-related quality of life","volume":"4","author":"Heatley","year":"2022","journal-title":"Crohns Colitis 360"},{"key":"2026100603513817300_gwag031-B13","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/ibd\/izy404","article-title":"Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy","volume":"25","author":"Chen","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2026100603513817300_gwag031-B14","doi-asserted-by":"publisher","first-page":"otac044","DOI":"10.1093\/crocol\/otac044","article-title":"Clinical effect of mirikizumab treatment on bowel urgency in patients with moderately to severely active ulcerative colitis and the clinical relevance of bowel urgency improvement for disease remission","volume":"5","author":"Dubinsky","year":"2023","journal-title":"Crohns Colitis 360"},{"key":"2026100603513817300_gwag031-B15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s41687-022-00438-2","article-title":"Incorporating patient experience into drug development for ulcerative colitis: development of the urgency numeric rating scale, a patient-reported outcome measure to assess bowel urgency in adults","volume":"6","author":"Dubinsky","year":"2022","journal-title":"J Patient Rep Outcomes"},{"key":"2026100603513817300_gwag031-B16","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s41687-022-00521-8","article-title":"Psychometric evaluation of the urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis","volume":"6","author":"Dubinsky","year":"2022","journal-title":"J Patient Rep Outcomes"},{"key":"2026100603513817300_gwag031-B17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jaut.2017.07.004","article-title":"Novel therapeutic targets for inflammatory bowel disease","volume":"85","author":"Argollo","year":"2017","journal-title":"J Autoimmun"},{"key":"2026100603513817300_gwag031-B18","author":"Takeda Canada Inc"},{"key":"2026100603513817300_gwag031-B19","author":"Takeda Pharmaceuticals U.S.A., Inc"},{"key":"2026100603513817300_gwag031-B20","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"2026100603513817300_gwag031-B21","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"2026100603513817300_gwag031-B22","first-page":"301","article-title":"Effectiveness of intravenous vedolizumab induction and dose escalation in ulcerative colitis and Crohn\u2019s disease; a large-scale, Canadian real-world cohort","volume":"12","author":"Bernard","year":"2024","journal-title":"United European Gastroenterol J"},{"key":"2026100603513817300_gwag031-B23","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1007\/s00535-018-1480-0","article-title":"Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease","volume":"53","author":"Schreiber","year":"2018","journal-title":"J Gastroenterol"},{"key":"2026100603513817300_gwag031-B24","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1016\/j.cgh.2016.02.016","article-title":"Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease","volume":"14","author":"Amiot","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026100603513817300_gwag031-B25","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.cgh.2025.06.015","article-title":"Bowel urgency in Crohn\u2019s disease: effects of mirikizumab in a randomized controlled phase 3 study","volume":"4","author":"Jairath","year":"026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026100603513817300_gwag031-B26","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s10620-021-06907-5","article-title":"Predictors of response to vedolizumab in patients with ulcerative colitis: results from the Greek VEDO-IBD cohort","volume":"67","author":"Bamias","year":"2022","journal-title":"Dig Dis Sci"},{"key":"2026100603513817300_gwag031-B27","author":"United States Food and Drug Administration"}],"container-title":["Journal of the Canadian Association of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcag\/article-pdf\/9\/5\/320\/70619722\/gwag031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcag\/article-pdf\/9\/5\/320\/70619722\/gwag031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:51:42Z","timestamp":1791273102000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcag\/article\/9\/5\/320\/8759751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,8,12]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jcag\/gwag031","relation":{},"ISSN":["2515-2084","2515-2092"],"issn-type":[{"value":"2515-2084","type":"print"},{"value":"2515-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,8,12]]}}}